Shattuck Labs, Inc. (NASDAQ:STTK) Receives $7.50 Consensus Target Price from Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have received a consensus rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $7.50.

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a report on Thursday, March 27th. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Finally, Leerink Partners began coverage on shares of Shattuck Labs in a report on Monday, March 17th. They issued an “outperform” rating and a $4.00 target price on the stock.

Hedge Funds Weigh In On Shattuck Labs

A number of institutional investors have recently modified their holdings of the business. Zacks Investment Management bought a new position in Shattuck Labs in the fourth quarter valued at about $25,000. Virtu Financial LLC acquired a new stake in shares of Shattuck Labs in the 4th quarter valued at approximately $30,000. AQR Capital Management LLC grew its holdings in shares of Shattuck Labs by 265.4% during the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Shattuck Labs during the 4th quarter worth approximately $45,000. Finally, Nuveen LLC bought a new position in Shattuck Labs in the 1st quarter valued at approximately $50,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Stock Down 14.6%

Shares of Shattuck Labs stock opened at $0.85 on Wednesday. The stock has a market capitalization of $40.89 million, a price-to-earnings ratio of -0.61 and a beta of 1.72. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $4.99. The company has a 50-day simple moving average of $1.00 and a two-hundred day simple moving average of $1.10.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 79.69%. On average, sell-side analysts anticipate that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.